Introduction
Recent studies have shown that about 10-20% of all thyroid cancers are non-invasive capsulated papillary follicular variant (NIFVPTC) [1, 2] . However, there is no consensus on papillary nuclear changes used in the diagnosis of NIFVPTC. Moreover, instead of NIFVPTC, some authors terminologically prefer the term "Non-invasive follicular thyroid neoplasm demonstrating papillary like nuclear features (NIFTP)" [3] . Although NIFPT is less agressive, there is a current debate on whether these patients are unnecessarily followed and treated. Contribution of clinical and laboratory findings obtained from the evaluation of thyroid nodules to the diagnosis of PTC (papillary thyroid carcinoma) infiltrative follicular variant and NIFPT is still unknown. In this study, we aimed to evaluate the characteristics of our cases with PTC follicular variant, which are accepted to have NIFPT according to new classification.
Patients and methods

Patient selection
A total number of 460 subjects with any PTC variant who had been followed up between the years 2010 and 2016 were enrolled in the study. Clinical and laboratory findings of 247 patients with follicular variant papillary thyroid carcinoma (FVPTC) were retrospectively examined and pathology specimens were reviewed according to recent NIFTP criteria [3] . We retrospectively examined 247 subjects and grouped them as Group 1: Encapsulated FVPTC without capsular invasion (recently called NIFTP) and Group 2: Encapsulated FVPTC with capsular invasion (IEFVPTC) (Group 1: 107 NIFTP; Group 2: 140 IEFVPTC). Patients who had another variant of thyroid carcinoma or diffuse/ multinodular variant of FVPTC, patients with tumors containing more than 1% true papillae and partially sampled tumors were excluded in the re-evaluation of the slides. The study protocol was approved by the Institutional Ethics Committee (TUTF-BAEK 2017/162).
Surgical Procedure and Follow up
Patients who underwent total thyroidectomy/lobectomy and post operative radioiodine ablation were classified in accordance with American Thyroid Association (ATA) guidelines [4] . Age, gender, thyroid function tests at the time of diagnosis, anti-TPO and anti-TG levels, preoperative neck ultrasonography findings, postoperative histopathologic features of tumor, thyroglobulin values, radioactive iodine-131 treatment recurrence, lymph node and distant metastasis and BRAF-KRAS-NRAS mutation status were recorded.
Clinicopathological criteria
Tumors exhibiting dominant follicular architecture (≤ 1% true papillae) and nuclear features of papillary thyroid carcinoma (2-3/3 nuclear score according to the alterations in nuclear size and shape; nuclear overlapping, nuclear enlargement, nuclear membrane irregularities; irregular nuclear contours, nuclear elongation, intranuclear pseudoinclusions, nuclear grooves, chromatin characteristics; nuclear chromatin clearing, glassy nuclei, peripheral margination of the chromatin) but not associated with necrosis, solid/trabecular/cribriform growth patterns, tall cell or columnar cell cytomorphology or more than 3 mitoses per 10 high power field (HPF) were classified as FVPTC [3] . FVPTCs completely surrounded by a fibrous capsule or clearly demarcated from the surrounding thyroid tissue were reclassified as NIFTP.
Pathology specimens of the patients with FVPTC were examined by 2 pathologists according to present diagnostic criteria. Findings of Group 1 and Group 2 were evaluated according to NIFTP diagnostic criteria described by using molecular and clinical results on March 20-21, 2015 in Boston, Massachusetts [3] . (Table 1 ,2).
BRAF Mutation analyses
Tumor tissue containing at least 30% of tumor cells was isolated from the sections of tumor tissue. Then, DNA purification was performed by using the nucleic acid isolation kit for paraffine embedded tissues ( Following the polymerase chain reaction (PCR) procedures pyrosequencing analyses were performed on PyroMarkQ24 by using sequencing primers including the Seq Primer BRAF 600 or Seq Primer BRAF 464-469.
Preoperative ultrasonography
Recently used "EU-TIRADS (Thyroid imaging reporting and data system)" classification method was utilized during thyroid USG. This method is used to determine the risk of malignancy of thyroid nodules. EU-TIRADS 1: Normal, EU-TIRADS 2: Benign, EU-TIRADS 3: Low risk, EU-TIRADS 4: Moderate risk, EU-TIRADS 5: High risk. In this study, especially high risk EU-TIRADS 5 nodule characteristics were evaluated. These include 4 main features; Not oval shape: taller than wide, irregular margins: spiculated or lobulated (at least 3 lobulations), Microcalcifications (multiple), Marked hypo-echogenicity (less echoic than the muscles) [5] . Thyroid ultrasonographic examinations of all patients were performed by an expert. 
Statistical Analysis
Results:
We retrospectively examined 247 subjects and grouped them as Group 1:
Encapsulated FVPTC without capsular invasion (recently called NIFTP) and Group 2:
Encapsulated FVPTC with capsular invasion (IEFVPTC) (Group 1: 107 NIFTP; Group 2: 140 IEFVPTC). There were no differences between the groups in terms of age, gender (Group 1: 81 F/26 M; Group 2: 116 F/24 M), thyroid function tests and the presence of lymphocytic thyroiditis. The mean follow-up period was 27 (17) months for Group 1, while it was 30 (20) months for Group 2. Central lymph node dissection revealed normal lymph nodes in 50 patients in Group 1, while 4 of 70 patients (5.7%) in Group 2 were found to have lymph node metastasis (P=0.14). There were no significant differences between the groups in terms of BRAF mutation positivity (P=0.08). One case in IEFVPTC group was found to have distant metastasis. Extrathyroidal extension was significantly more common in the subjects with IEFVPTC ( Table 3 ). Second dose radioactive iodine-131 was necessary in none of NIFTP cases and in 2 of IEFVPTC subjects.
The number of patients who undergone central lymph node metastasis was 50 and 74 in NIFTP and IEFVPTC groups, respectively. No statistically significant difference was present between these cases in terms of age, gender and follow-up period. Although there was no statistically significant difference between two groups who undergone preoperative thyroid nodule fine needle aspiration biopsy in terms of the results, undetermined atypia and malignancy in IEFVPTC group and follicular neoplasm in NIFTP group was more common, approaching close to statistical significance (Table 4 ). Preoperative neck ultrasonography revealed irregular border in 6.5% of pathologic nodules of NIFTP group, while it was 15.7% for IEFVPTC group (P=0.02), (Table 5) . Multivariable logistic regression model was utilized using age-gender adjusted ultrasonographic findings (hypoechoic appearance, internal vascularization, microcalcification and irregular border). Lymph node metastasis was excluded from the analysis because lymph node dissection was not performed in all patients.
Additionally, multivariable analysis (binary logistic regression) showed that follicular variant papillary thyroid cancer was positively associated only with irregular border and extrathyroidal extension (P=0.02, P<0.001, respectively) ( Table 6 ).
Discussion
This study was designed to review clinical and pathologic evaluation of non-invasive EFVPTC which is classified as a malignancy despite its indolent nature. In the study by Rosario [6] which evaluted preoperative thyroid ultrasonography findings, data of 120 patients from NIFTP group and 54 patients from EFVPTC were compared and highly suspicious nodule findings were found to be more common especially in EFVPTC group. However, since the number of the subjects with suspicious nodule was 6 (5%) in NIFTP group and 8 (14.8%) in EFVPTC, it was stated that further studies including more subjects are required. In our study, In FVPTC group, ultrasonographically detected nodules with irregular borders were more common, when compared to NIFTP group (P = 0.02) ( Table 5 ). In a mini metaanalysis by Maletta et al. [7] , Bethesda categories of preoperative fine needle aspiration biopsies were re-categorized after the diagnosis of NIFTP and malignancy risk was re-evaluated. The risk of malignancy was found to change upto 66% especially in Bethesda category 4. In our study, preoperative fine needle aspiration biopsy of especially NIFTP subjects showed bethesta category 4 to be more common. Therefore, we suggest that prospective FNAB molecular studies may be valuable in the diagnosis of NIFTP. In the literature, only 2 (0.6%) of 352 well-documented noninvasive FVPTC cases had recurrence. In one of these, excision was incomplete, while noninvasive characteristic of tumor was disputable in the other. In general, data suggest that this lesion rarely has negative results in the absence of invasion [8] [9] [10] [11] [12] [13] [14] . In our study, none of the patients with NIFTP developed recurrence during follow-up period. In the study by Nikiforov et al. [15] , which was important in building a consensus on the main histopathologic features of NIFTP, non-invasive FVPTC (n:109) and invasive FVPTC (n:101) were compared. Most of the subjects with NIEFVPTC were lobectomized and all had no RAI treatment. The decision of radioactive treatment was made considering ATA criteria [4] .
These criteria are; Macroscopic tumoral invasion to perithyroidal soft tissues, incomplete tumor resection, distant metastasis (M1), post-operative significant serum Tg elevation suspicious for distant metastasis, pathological lymph node metastasis ≥3 cm in longest diameter (N1), follicular thyroid cancer with disseminated vascular invasion (>4 foci) [4] . In their study, Szczepanek-Parulska et al. [16] mentioned that serum thyroglobulin level was the most important factor suggesting poor response to radioiodine treatment in the patients with differentiated thyroid cancer. They suggested that it should be considered for treatment, follow-up and also to predict the prognosis. In our study, serum thyroglobulin levels measured during follow-up did not increase in the patients with NIFTP. In this comparison, no BRAFV600E mutation, distant metastasis and mortality were seen during follow-up period of the cases with NIEFPTC. On the other hand, in IEFVPTC group which mostly included subjects who undergone total thyroidectomy and RAI treatment, mortality occured in 7 patients (5 related to distant metastasis and 2 of them related to disease itself). This study suggested that NIEFVPTC has a less agressive course and these cases should be categorized as NIFTP. In contrast to the study by Nikiforov et al., one of our cases with NIFTP was found to have BRAFV600E mutation, a poor prognostic factor, while distant and lymph node metastasis were similarly rare when compared to ECFVPTC group (Table 3) . Uiju Cho et al. [17] suggested that evaluation of cases who undergone standart lymph node dissection is more important in prognostic evaluation of subjects with NIFTP. In the study by Uiju Cho et al., patients who undergone standart central lymph node dissection were histopathologically grouped into two as the ones with ≤1% papillae (n:105) and the cases with no papillae.
Among these, the rate of BRAFV600E mutation and lymph node metastasis was 10% and %3, respectively, in the group with ≤1% papillae, while in the group with no papillae, none of the patients had BRAFV600E mutation and 3% of them had lymph node micrometastasis. As a result, it was stated that further prospective studies are required to accept NIFTP as neoplasm. In the literature, subjects with undeterminate thyroid nodule fine needle aspiration cytology have been evaluated by 7-gene mutation and rearrangement (BRAF, RAS, RET / PTC, PAX8 / PPARc) [18] . It has been suggested that these tests could not safely exclude malignancy. Use of a 167 GEC has been proposed as a rule-out test due to relatively high sensitivity (92%) and Net Present Value (93%), as reported in a prospective multicenter study [19] . In addition, relatively low specificity of 167 GEC test (48%-53%) has shown that it could not establish malignancy criteria for indeterminate nodules. Alexander et al. [20] reported that the prevalence of 167 GEC benign readings varied up to 29% among institutions, which was not statistically significant. In In conclusion, subjects diagnosed as NIFTP after a careful histopathologic examination developed no recurrence during the first 3 years. However, one of the patients with NIFTP was found to have BRAFV600E mutation as poor prognostic factor. Further prospective studies are required for differential diagnosis of NIFTP especially in the patients who underwent preoperative FNAB. In addition, further prospective studies are necessary for prognostic evaluation of the subjects with NIFTP. 
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